Navigation Links
IDEV Technologies Completes $46 Million Preferred Stock Financing With Piper Jaffray and Additional Strategic Investor

WEBSTER, Texas, Oct. 7 /PRNewswire/ -- IDEV Technologies, Incorporated (IDEV), an emerging leader in the development and commercialization of minimally invasive medical technologies, today announced that it has completed a $46 million Series D round of financing, with Piper Jaffray & Co.'s Merchant Banking Fund (PJC Capital LLC) and a leading strategic global healthcare company as the two new investors.  The financing also included strong support and additional investment from existing venture capital firms PTV Sciences, Bay City Capital, RiverVest Venture Partners and Heron Capital.

The proceeds from the financing will be used to fund SUPERB, the ongoing, multi-center IDE superficial femoral artery clinical trial for the company's self-expanding SUPERA® stent, new clinical trials in support of other peripheral artery indications, the development of new interventional products, and sales and marketing initiatives to support continued revenue growth.  IDEV continues to achieve success from the recent European launch of its SUPERA VERITAS™ Peripheral Vascular System, an easy to use, reliable and precise stent delivery system developed to deliver the SUPERA stent.  In addition, the company is pleased with the positive market reaction to the initial data released from a European registry which yielded promising results in the superficial femoral (SFA) and popliteal arteries. The company is very encouraged by these preliminary data and believes it demonstrates the durability of the innovative self-expanding SUPERA stent.  

Christopher M. Owens, President and CEO of IDEV, said, "We have strong support from our existing investors and we are excited to be working with our two new corporate partners, Piper Jaffray, a leading international investment bank and institutional securities firm with significant experience in the medical technology sector and the additional new investor, a leading strategic global healthcare company.  We appreciate the enthusiastic interest and financial support of both existing and new investors.  This is an exciting time for IDEV.  In addition to the completed financing and the successful European launch of VERITAS, we are seeing significant progress on our key initiatives such as the enrollment of our SUPERB superficial femoral artery IDE trial for the SUPERA stent and for the new product launches scheduled for this year.  Furthermore, I am pleased that we continue to achieve accelerated revenue growth while building a strong foundation for the future."

Proceeds from the financing will advance IDEV's strategy of creating a world-class interventional platform to address the unmet clinical needs of the nearly 120 million patients who suffer from peripheral artery disease.

About IDEV Technologies, IncorporatedIDEV Technologies, Incorporated (IDEV) is an innovator and developer of next generation medical devices for use in the interventional radiology, vascular surgery and cardiology marketplace.  IDEV's worldwide headquarters is located in Webster, Texas and its European headquarters is located in Beuningen, The Netherlands.  Please visit

The SUPERA stent is currently indicated in the US for the palliative treatment of biliary strictures produced by malignant neoplasms and in Europe for both the treatments of biliary strictures produced by malignant neoplasms and for peripheral vascular use following failed percutaneous transluminal angioplasty (PTA).Contact:

William W. BurkeExecutive Vice President & Chief Financial OfficerIDEV Technologies, Incorporated(281) 525-2000Donna LucchesiVice President Global MarketingIDEV Technologies, Incorporated(281) 525-2000

SOURCE IDEV Technologies, Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. DiFUSION Technologies Adds Accomplished Senior Management Team
2. DiFUSION Technologies Receives 510(k) Clearance of Xiphos™ Interbody Implants for Spinal Fusion
3. medSage Technologies Introduces Revolutionary Universal CPAP Monitor
4. All-Time High in Q Orders for Wound Management Technologies, Inc.
5. Reportlinker Adds Nanobiotechnologies - Applications, Markets and Companies
6. Thompson Group Acquires Hamilton Sundstrands Applied Instrument Technologies
7. Objet Geometries and Javelin Technologies Form Strategic Distribution Partnership for 3D Printers
8. Delta Health Technologies ClinicalVirtuoso™ Targets Homecare Therapists
9. Medisafe 1 Technologies Successfully Tests Prototype of Patented Syringe Locking Device
10. Palatin Technologies to Present at 9th Annual BIO Investor Forum
11. Wound Management Technologies, Inc. Furthers its Government Initiatives and Business Development within the Veterans Health Administration
Post Your Comments:
(Date:6/24/2016)... , June 24, 2016 Research and ... Market for Companion Diagnostic Tests" report to their offering. ... for Companion Diagnostics The World Market for ... personalized medicine diagnostics. Market analysis in the report includes the ... Market (In Vitro Diagnostic Kits) by Region (N. America, EU, ...
(Date:6/23/2016)... , June 23, 2016  MedSource announced today ... its e-clinical software solution of choice.  This latest ... possible value to their clients by offering a ... preferred relationship establishes nowEDC as the EDC platform ... MedSource,s full-service clients.  "nowEDC has long been a ...
(Date:6/23/2016)... , June 23, 2016 Roche (SIX: RO, ... clearance for its Elecsys BRAHMS PCT (procalcitonin) assay as ... or septic shock. With this clearance, Roche is the ... fully integrated solution for sepsis risk assessment and management. ... bacterial infection and PCT levels in blood can aid ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library on June ... , brings up a new, often overlooked aspect of head lice: the parasite’s ability to ... is not a common occurrence, but a necessary one in the event that lice have ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin ... injury. Recently, he has implemented orthobiologic procedures as a method for treating his ... of the first doctors to perform the treatment. Orthobiologics are substances that orthopaedic ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic events may suffer ... unhealthy avenues, such as drug or alcohol abuse, as a coping mechanism. To avoid ... healthy coping following a traumatic event. , Trauma sufferers tend to feel a range ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg Traurig, P.A. announced ... attorneys chosen by their peers for this recognition are considered among the top 2 ... received special honors as members of this year’s Legal Elite Hall of Fame: ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. are sharpening their pencils ... an essay contest in which patients and their families pay tribute to a genetic ... 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. ...
Breaking Medicine News(10 mins):